Literature DB >> 24322174

SIRT3 expression as a biomarker for better prognosis in gastric cancer.

Kuo-Hung Huang1, Chia-Chi Hsu, Wen-Liang Fang, Chin-Wen Chi, Ming-Ta Sung, Hwa-Li Kao, Anna Fen-Yau Li, Pen-Hui Yin, Muh-Hwa Yang, Hsin-Chen Lee.   

Abstract

BACKGROUND: SIRT3-mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase sirtuin-3-plays an important role in regulating cell metabolism and carcinogenesis. The role of SIRT3 in gastric cancer has not yet been investigated.
METHODS: A total of 221 gastric cancer patients who underwent curative surgery were enrolled at the Department of Surgery, Taipei Veterans General Hospital. SIRT3 expression in gastric tissues and tumors were examined in these patients using immunohistochemical staining. Clinicopathologic characteristics and survival were analyzed and compared in gastric cancer patients with or without SIRT3 expression.
RESULTS: The 5-year survival rates of patients with or without SIRT3 expression were 51.2 and 39.1 %, respectively (p = 0.005). The 5-year disease-free survival rates of patients with or without SIRT3 expression were 49.6 and 38.0 %, respectively (p = 0.010). Microscopic features showed that there are more poor cell differentiation (p = 0.001), more diffuse-type Lauren's histology (p = 0.018), and more scirrhous-type stromal reactions (p = 0.027) in gastric cancer without SIRT expression. Multivariate analysis with overall survival as an endpoint showed that age (p < 0.001), Lauren's histology (p = 0.007), stromal reaction (p = 0.035), TNM pathologic N category (p < 0.001), and SIRT3 expression (p < 0.001) were significantly correlated with gastric cancer.
CONCLUSIONS: Gastric cancer patients with SIRT3 expression have a better prognosis than those without. SIRT3 expression is an independent prognostic marker for overall survival and may act as a tumor suppressor in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24322174     DOI: 10.1007/s00268-013-2359-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  15 in total

1.  Nodal dissection for patients with gastric cancer: a randomised controlled trial.

Authors:  Chew-Wun Wu; Chao A Hsiung; Su-Shun Lo; Mao-Chin Hsieh; Jen-Hao Chen; Anna Fen-Yau Li; Wing-Yiu Lui; Jacqueline Whang-Peng
Journal:  Lancet Oncol       Date:  2006-04       Impact factor: 41.316

2.  Gastric carcinoma. A pathobiological classification.

Authors:  S C Ming
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

3.  Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation.

Authors:  Yuan-Yuan Zhang; Li-Ming Zhou
Journal:  Biochem Biophys Res Commun       Date:  2012-05-17       Impact factor: 3.575

Review 4.  SIRT3 and cancer: tumor promoter or suppressor?

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Eric Verdin; Yvonne L Kapila
Journal:  Biochim Biophys Acta       Date:  2011-05-07

5.  SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization.

Authors:  Lydia W S Finley; Arkaitz Carracedo; Jaewon Lee; Amanda Souza; Ainara Egia; Jiangwen Zhang; Julie Teruya-Feldstein; Paula I Moreira; Sandra M Cardoso; Clary B Clish; Pier Paolo Pandolfi; Marcia C Haigis
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

6.  SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress.

Authors:  Hyun-Seok Kim; Krish Patel; Kristi Muldoon-Jacobs; Kheem S Bisht; Nukhet Aykin-Burns; J Daniel Pennington; Riet van der Meer; Phuongmai Nguyen; Jason Savage; Kjerstin M Owens; Athanassios Vassilopoulos; Ozkan Ozden; Seong-Hoon Park; Keshav K Singh; Sarki A Abdulkadir; Douglas R Spitz; Chu-Xia Deng; David Gius
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation.

Authors:  Matthew D Hirschey; Tadahiro Shimazu; Eric Goetzman; Enxuan Jing; Bjoern Schwer; David B Lombard; Carrie A Grueter; Charles Harris; Sudha Biddinger; Olga R Ilkayeva; Robert D Stevens; Yu Li; Asish K Saha; Neil B Ruderman; James R Bain; Christopher B Newgard; Robert V Farese; Frederick W Alt; C Ronald Kahn; Eric Verdin
Journal:  Nature       Date:  2010-03-04       Impact factor: 49.962

8.  Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma.

Authors:  Chris Zhiyi Zhang; Lili Liu; Muyan Cai; Yinghua Pan; Jia Fu; Yun Cao; Jingping Yun
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

9.  Altered sirtuin expression is associated with node-positive breast cancer.

Authors:  N Ashraf; S Zino; A Macintyre; D Kingsmore; A P Payne; W D George; P G Shiels
Journal:  Br J Cancer       Date:  2006-09-26       Impact factor: 7.640

10.  Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin.

Authors:  Lara Gibellini; Marcello Pinti; Milena Nasi; Sara De Biasi; Erika Roat; Linda Bertoncelli; Andrea Cossarizza
Journal:  Cancers (Basel)       Date:  2010-06-14       Impact factor: 6.639

View more
  19 in total

Review 1.  Using mitochondrial sirtuins as drug targets: disease implications and available compounds.

Authors:  Melanie Gertz; Clemens Steegborn
Journal:  Cell Mol Life Sci       Date:  2016-03-23       Impact factor: 9.261

Review 2.  Role of the mitochondrial stress response in human cancer progression.

Authors:  Sheng-Fan Wang; Shiuan Chen; Ling-Ming Tseng; Hsin-Chen Lee
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-23

3.  SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1.

Authors:  Liang Wang; Wei-Yan Wang; Li-Ping Cao
Journal:  Int J Clin Exp Med       Date:  2015-04-15

4.  The sirtuin family in cancer.

Authors:  Luis Filipe Costa-Machado; Pablo J Fernandez-Marcos
Journal:  Cell Cycle       Date:  2019-07-25       Impact factor: 4.534

5.  Pro-Proliferative Function of Mitochondrial Sirtuin Deacetylase SIRT3 in Human Melanoma.

Authors:  Jasmine George; Minakshi Nihal; Chandra K Singh; Weixiong Zhong; Xiaoqi Liu; Nihal Ahmad
Journal:  J Invest Dermatol       Date:  2015-12-29       Impact factor: 8.551

Review 6.  Somatic alterations in mitochondrial DNA and mitochondrial dysfunction in gastric cancer progression.

Authors:  Hsin-Chen Lee; Kuo-Hung Huang; Tien-Shun Yeh; Chin-Wen Chi
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 7.  Role of mitochondrial dysfunction in cancer progression.

Authors:  Chia-Chi Hsu; Ling-Ming Tseng; Hsin-Chen Lee
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

8.  The Prognostic and Clinicopathological Roles of Sirtuin-3 in Various Cancers.

Authors:  Fei-Yuan Yu; Qian Xu; Dan-Dan Wu; Andy T Y Lau; Yan-Ming Xu
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

9.  SIRT3 acts as a novel biomarker for the diagnosis of lung cancer: A retrospective study.

Authors:  Feng Tao; Chao Gu; Na Li; Ying Ying; Yongzhi Feng; Dan Ni; Qi Zhang; Qinfeng Xiao
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

Review 10.  Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease.

Authors:  Aneesa Ansari; Md Shahedur Rahman; Subbroto K Saha; Forhad K Saikot; Akash Deep; Ki-Hyun Kim
Journal:  Aging Cell       Date:  2016-09-29       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.